Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AGS-003 |
| Synonyms | |
| Therapy Description |
AGS-003 (Rocapuldencel-T) is an immunotherapy that comprises autologous dendritic cells transfected with patient tumor-derived RNA and CD40LG (CD40L) RNA, which may result in induction of an anti-tumor immune response (PMID: 25901286, PMID: 32034074). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AGS-003 | Rocapuldencel-T | AGS-003 (Rocapuldencel-T) is an immunotherapy that comprises autologous dendritic cells transfected with patient tumor-derived RNA and CD40LG (CD40L) RNA, which may result in induction of an anti-tumor immune response (PMID: 25901286, PMID: 32034074). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02170389 | Phase I | AGS-003 | Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer | Terminated | USA | 0 |